Paper Titles
Biopolymer Chain Folding and Biomolecular Recognition: A Quantum Decoherence Theory Approach
p.513
Biphasic Calcium Phosphate/Poly-(DL-Lactide-Co-Glycolide) Biocomposite as Filler and Blocks for Reparation of Bone Tissue
p.519
Alginate Microbeads as Potential Support for Cultivation of Bone Marrow Stromal Cells
p.525
Mathematical Modeling of Cell Distribution in Alginate Microbeads
p.531
Synthesis and Characterization of Biphasic Calcium Phosphate/ Poly-(DL-Lactide-Co-Glycolide) Biocomposite
p.537
Effects of Fullerenol C60(OH)24 on Cytotoxicity Induced by Antitumor Drugs on Human Breast Carcinoma Cell Lines
p.543
Radioprotective Efficiency of Fullerenol in Irradiated Mice
p.549
Kinetics of Interaction between Fullerol C60(OH)24 and Polyacrylic Hydrogels
p.555
Appearance of a Hard Layer (α – Case) on the Surface of Ti-6Al-4V Surgical Implant Castings
p.561

Effects of Fullerenol C60(OH)24 on Cytotoxicity Induced by Antitumor Drugs on Human Breast Carcinoma Cell Lines

Article Preview

Abstract:

The aims of this paper were to investigate cell growth activity of fullerenol C60(OH)24, its modulating effect on antitumor drug-induced cytotoxicity, and genotoxic influence of fullerenol at nanomolar concentrations. Human breast cancer cell lines, MCF-7 and MDA-MB-231, were treated with fullerenol at concentrations from 0.9 to 3.9 µg/ml alone or simultaneously with antitumor drugs (doxorubicin, cisplatin, taxol, and tiazofurin; IC50 concentrations) for 2 hours. Growth inhibition was evaluated by colorimetric SRB assay after recovery period of 24, 48, and 96 hours. The genotoxic examination was performed using sister chromatid exchange test and micronucleus assay, at fullerenol concentration ranging from 1 to 5 µg/ml. The fullerenol alone mildly inhibits the growth of both cell lines. Simultaneous administration of fullerenol and antitumor drugs strongly suppressed antitumor drug-induced cytotoxicity. The rate of cytotoxicity inhibition depended on fullerenol concentration, type of antitumor drug and cell line. Protection against doxorubicin and cisplatin was more pronounced than against taxol and tiazofurin. Fullerenol was not found to be genotoxic to investigated cell lines.

You might also be interested in these eBooks
Current Research in Advanced Materials and Processes View Preview

Info:

Periodical:

Materials Science Forum (Volume 494)

Pages:

543-548

DOI:

https://doi.org/10.4028/www.scientific.net/MSF.494.543

Citation:

Cite this paper

Online since:

September 2005

Authors:

V. Kojić, D. Jakimov, G. Bogdanović, A. Djordjević

Keywords:

Breast Cancer, C60(OH)24, Cell Line, Cisplatin, Cytogenetic Tests, Cytotoxicity Tests, Doxorubicin, Fullerenol, Genotoxicology, Taxol, Tiazofurin

Export:

RIS, BibTeX

Price:

Permissions CCC:

Request Permissions

Permissions PLS:

Request Permissions

Сopyright:

© 2005 Trans Tech Publications Ltd. All Rights Reserved

Share:

Citation:

References

[1] H.W. Kroto, J.R. Heath, S.C. O'Brien, R.F. Curl, R.E. Smaliey, C60: Buckminsterfullerene, Nature (London) 318 (1985), p.162.

DOI: 10.1038/318162a0

Google Scholar

[2] A. Djordjevic, Chemical derivatisation of fullerene C60 and biological investigation (Zaduzbina Andrijevic, Beograd, 2002).

Google Scholar

[3] C. Yu, J.B. Bhonsle, L.Y. Wang, J.G. Lin, B-J. Chen and L.Y. Chiang, Fullerene Science and Technology, Vol. 5 (1997), p.1407.

Google Scholar

[4] S.C. Chuech, M.K. Lai, M.S. Lee L.Y. Chaing T.I. Ho and S.C. Chen, Transplantation ProCeedings, Vol. 31 (1999), p. (1976).

Google Scholar

[5] H-S. Lai, W.J. Chen and L.Y. Chaing, World Journal of Surgery, Vol. 24 (2000), p.450.

Google Scholar

[6] T. -H. Ueng, H. -W. Wang and L. Y. Chaing, Fullerene Science and Technology, Vol. 7 (1999), p.681.

Google Scholar

[7] G. Bogdanović, M. Vojinović-Miloradov, V. Kojić, A. Đorđević, J. Čanadi, Đ. Koruga, V.V. Baltić and D. Tabš, Archive of Oncology, 5/3 (1997), p.147.

Google Scholar

[8] D. Jakimov, G. Bogdanovic, M. Baltić, S. Turšijan, L. Aleksić, A. Đorđević, J. Mrđanović and M. Vojinović-Miloradov, Advances in simulation, systems theory and systems engineering, (WSEAS Press (2002), pp.117-122).

Google Scholar

[9] G. Bogdanovic, V. Kojic, A. Đorđević, J. Čanadanovic-Brunet, M. Vojinović-Miloradov and V.V. Baltić, Toxicology in vitro, (2004), p.629.

DOI: 10.1016/j.tiv.2004.02.010

Google Scholar

[10] L.P. Zakharenko, I.K. Zakharov, E.A. Vasyunina, T.V. Karamysheva, A.M. Danilenko and A.A. Nikiforov, Russian Journal of Genetics, Vol. 33/3 (1997), p.327.

Google Scholar

[11] G. Bogdanović, J. Raletić-Savić, N. Marković, Arch. Oncol., Vol. 2 (1994), p.181.

Google Scholar

[12] A. Djordjevic, M. Vojinovic-Miloradov, N. Petranovic, A. Devecerski, D. Lazar and B. Ribar, Fullerene Sciences and Technology, Vol. 6 (1998), p.689.

Google Scholar

[13] P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. i Bokesch, S. Kenney and M. R. Boyd, Drug Screening. Articles, Vol. 82 (1990), p.1107.

DOI: 10.1093/jnci/82.13.1107

Google Scholar

[14] Cytogenetic analysis for radiation dose assessment - a manual (Technical reports series No. 405, International Atomic Energy Agency, Vienna, 2001).

Google Scholar

[15] Guide to short-term tests for detecting mutagenic and carcinogenic chemicals. Prepared for the International Programme on Chemical Safety (IPCS) by the International Commission for Protection Against Mutagens and Carcinogens, World Health Organisation, Geneva, (1985).

DOI: 10.1177/096032718600500622

Google Scholar

[16] J.M. Barch, The ACT cytogenetic laboratory manual - 2nd edition (Raven Press, New York, 1991).

Google Scholar

[17] R.S. Verma, A. Babu, Human chromosomes: Principles and techniques - 2nd edition. (McGraw-Hill, Health professions division, New York, 1995).

Google Scholar

[18] M Fenech, Drug Discovery Today, Vol. 7 No. 22 (2002), p.1128.

Google Scholar

[19] T.V. De Vita, J.R.S. Hellman and A.S. Rosenberg, Cancer principles and practice of oncology (Philadelphia: Lippincott-Raven, 1997: 1-16, 375-512).

Google Scholar

[20] G. Weber and N. Preida, Adv. Enzime Regul., Vol. 34 (1994), p.71.

Google Scholar

[21] Q. Li, Y. Xiu, X. Zhang, R. Liu, Q. Du, X. Shun, S. Chen and W. Li, Nuclear Medicine and Biology, Vol. 29 (2002), p.707.

Google Scholar

[22] C.M. Sayes, J.D. Fortner, W. Guo, D. Lyon, A.D. Boyd, K.D. Ausman, Y.J. Tao, B. Sitharaman, L.J. Wilson, J.B. Hughes, J.L. West and V.L. Colvin, Nano Letters Vol. 0 (2004), P. A-G.

DOI: 10.1021/nl0489586

Google Scholar